Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-1.31 Insider Own0.50% Shs Outstand147.12M Perf Week11.06%
Market Cap10.99B Forward P/E- EPS next Y-1.23 Insider Trans11.69% Shs Float146.78M Perf Month8.15%
Income-186.60M PEG- EPS next Q-0.22 Inst Own99.80% Short Float3.72% Perf Quarter20.34%
Sales627.10M P/S17.53 EPS this Y-34.70% Inst Trans-0.15% Short Ratio4.88 Perf Half Y26.22%
Book/sh10.01 P/B7.46 EPS next Y6.10% ROA-8.70% Target Price84.75 Perf Year12.03%
Cash/sh5.69 P/C13.14 EPS next 5Y25.00% ROE-13.50% 52W Range55.04 - 84.25 Perf YTD6.20%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-11.32% Beta0.92
Dividend %- Quick Ratio6.20 Sales past 5Y13.10% Gross Margin83.00% 52W Low35.74% ATR2.32
Employees1341 Current Ratio7.30 Sales Q/Q40.20% Oper. Margin-23.00% RSI (14)62.08 Volatility3.98% 3.26%
OptionableYes Debt/Eq0.45 EPS Q/Q-53.30% Profit Margin-29.80% Rel Volume1.40 Prev Close71.00
ShortableYes LT Debt/Eq0.45 EarningsOct 23 AMC Payout- Avg Volume1.12M Price74.71
Recom2.00 SMA205.69% SMA507.47% SMA20011.91% Volume1,559,191 Change5.23%
19-Feb-14Reiterated Barclays Equal Weight $73 → $76
14-Jan-14Reiterated Deutsche Bank Buy $75 → $85
10-Jan-14Downgrade Barclays Overweight → Equal Weight $75 → $73
25-Oct-13Reiterated Barclays Overweight $70 → $75
18-Sep-13Downgrade Stifel Buy → Hold
26-Jul-13Reiterated Stifel Buy $67 → $70
03-Apr-13Reiterated Barclays Overweight $54 → $70
20-Mar-13Reiterated RBC Capital Mkts Outperform $58 → $64
20-Mar-13Reiterated Deutsche Bank Hold $45 → $59
22-Feb-13Reiterated RBC Capital Mkts Outperform $55 → $58
01-Feb-13Reiterated UBS Buy $53 → $67
22-Jan-13Upgrade Stifel Nicolaus Hold → Buy $67
06-Nov-12Reiterated Barclays Overweight $46 → $54
06-Nov-12Downgrade Brean Capital Buy → Hold
28-Sep-12Reiterated Summer Street Research Buy $45 → $52
27-Aug-12Downgrade Deutsche Bank Buy → Hold $40 → $45
24-Aug-12Initiated Barclays Overweight $46
12-Apr-12Initiated UBS Buy $43
26-Mar-12Initiated Canaccord Genuity Buy $43
19-Mar-12Upgrade Brean Murray Hold → Buy $41
21-Oct-14 04:30PM  Will BioMarin (BMRN) Disappoint This Earnings Season? Zacks +5.23%
09:29AM  Some Potential Targets for Shire to Buy With $1.6B in Free Money at TheStreet
14-Oct-14 06:09AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
08-Oct-14 08:00AM  BioMarin to Host Third Quarter 2014 Financial Results Conference Call and Webcast on Thursday, October 23 at 4:30pm ET GlobeNewswire
30-Sep-14 07:20AM  Catalyst Pharma Closer to Unconscionable Price Hike for Rare-Disease Drug at TheStreet
29-Sep-14 04:05PM  Catalyst Pharma's lead drug succeeds in late-stage study Reuters
25-Sep-14 05:24PM  BioMarin (BMRN) Faces Threat of Genericization for Kuvan Zacks
08:35AM  5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential at 24/7 Wall St.
24-Sep-14 05:21PM  FDA Receives Paragraph IV Notice Letter for KUVAN(R) (sapropterin dihydrochloride) Tablets GlobeNewswire
23-Sep-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
15-Sep-14 08:00AM  BioMarin Named by CenterWatch as One of the Fastest Developers of Medicines GlobeNewswire
10-Sep-14 08:00AM  BioMarin to Attend Upcoming Investor Conferences in London GlobeNewswire
05-Sep-14 04:35PM  Merck KGaA's Kuvan Effective in Under-4 Year Olds Zacks
03-Sep-14 11:50AM  Credit Suisse Positive on Some Biotechs, Very Cautious on Others at 24/7 Wall St.
09:10AM  Biotech Stock Roundup: United Therapeutics Up on Court Ruling, Amgen Files PCSK9 Inhibitor Zacks
31-Aug-14 03:00AM  Early data suggest Sanofi, Regeneron drug may halve heart risk Reuters
28-Aug-14 01:04PM  NVO, BMRN And ILMN, 3 Health Care Stocks Pushing The Sector Lower at TheStreet
27-Aug-14 04:20PM  BioMarin Cuts '14 Revenue View after Voucher Sale Evaluation Zacks
06:40AM  Can BioMarin Pharmaceutical (BMRN) Run Higher on Strong Earnings Estimate Revisions? Zacks
26-Aug-14 04:21PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Results of Operations and Financial Condition EDGAR Online
19-Aug-14 08:00AM  BioMarin to Present at Upcoming Investor Conferences GlobeNewswire
14-Aug-14 01:32PM  Temasek Adds China Holdings With JD.com, Cheetah Stakes at Bloomberg
08-Aug-14 01:04PM  BIOMARIN PHARMACEUTICAL INC Financials EDGAR Online Financials
10:29AM  Scott Drake, CEO, and Guy A. Childs, CFO of The Spectranetics Corporation (SPNC), Interview with The Wall Street Transcript Wall Street Transcript
07-Aug-14 11:40AM  NPS Pharma Reports Earnings in Q2 on Strong Gattex Sales Zacks
07:04AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
06-Aug-14 04:02PM  BioMarin Weathers The Storm Benzinga
05-Aug-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
07:33AM  Saving kids: When unapproved drugs are the only hope at CNBC
01-Aug-14 01:28PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
31-Jul-14 04:00PM  BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up Zacks
01:34PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
30-Jul-14 04:08PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Sells Priority Review Voucher for $67.5 Million GlobeNewswire
04:01PM  BioMarin Announces Second Quarter 2014 Financial Results GlobeNewswire
11:04AM  Biotech Stock Roundup: Gilead's Sovaldi & Biogen's Tecfidera Impressive Run Continues Zacks
07:07AM  Q2 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN
23-Jul-14 02:15PM  [video] What's coming in biotech? at CNBC
12:20PM  Biogen's Q2 Earnings Surpass Expectations, Tecfidera Shines Zacks
12:10PM  Cubist Misses Q2 Earnings Estimates on Weak Cubicin Sales Zacks
08:00AM  Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation GlobeNewswire
18-Jul-14 08:21AM  Zacks Rank #1 Additions for Friday Zacks +5.88%
16-Jul-14 03:30PM  Arena Pharmaceuticals' Pain Candidate Gets New U.S. Patent Zacks
15-Jul-14 06:04AM  Cramer's Lightning Round - BioMarin Deserves To Be Higher (7/14/14) at Seeking Alpha
06:00AM  'Mad Money' Lightning Round: Wait on Whole Foods at TheStreet
14-Jul-14 06:52PM  Lightning Round: Whole Foods, Apache & more at CNBC
03:45PM  Will Johnson & Johnson (JNJ) Beat this Earnings Season? Zacks
09-Jul-14 08:00AM  BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET GlobeNewswire
08-Jul-14 05:10PM  BioMarin's Vimizim Gets Canadian Nod Zacks
07-Jul-14 08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome PR Newswire
08:00AM  BioMarin Announces Health Canada Approval of VIMIZIM (elosulfase alfa) for the Treatment of Morquio A Syndrome CNW Group
03-Jul-14 07:06AM  Why BioMarin Pharmaceutical (BMRN) Could Beat Earnings Estimates Again Zacks
30-Jun-14 05:00PM  Biogen Hemophilia Drugs Launch Into The Unknown at Investor's Business Daily
02:06AM  Lifting the Curtain on Healthcare's Most Expensive Drugs at Motley Fool
20-Jun-14 02:19PM  Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate at TheStreet +5.90%
12-Jun-14 02:11PM  Amicus Therapeutics Still A "Show Me" Story at Seeking Alpha
08:30AM  Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More at 24/7 Wall St.
07:53AM  How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? at TheStreet
10-Jun-14 11:02AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a EDGAR Online
08:00AM  BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th GlobeNewswire
09-Jun-14 07:54AM  How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? at TheStreet
03-Jun-14 01:02PM  Drugs Stocks On The Rise With Help From 3 Stocks at TheStreet +6.17%
12:01PM  Life After Pfizer: AstraZeneca Hopes for Oncology Success at Motley Fool
29-May-14 10:40AM  BioMarin's Pipeline Advances Zacks
28-May-14 08:32AM  Retrophin Names Aselage COO at theflyonthewall.com
27-May-14 08:40AM  BioMarin doses first patient in Phase 3 INSPIRE trial with BMN 701 at theflyonthewall.com
08:00AM  BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease GlobeNewswire
23-May-14 08:31AM  BioMarin has a conference call hosted by JPMorgan at theflyonthewall.com
15-May-14 09:47AM  Temasek Boosted Stake in U.S. Health Care Industry Last Quarter at Bloomberg
06:47AM  BioMarin data compares well as monotherapy, says William Blair at theflyonthewall.com
05:40AM  ASCO abstracts 'surprisingly bland,' says Piper Jaffray at theflyonthewall.com
14-May-14 10:30AM  Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders at TheStreet
08-May-14 06:00AM  'Mad Money' Lightning Round: BioMarin Is for Real at TheStreet
04:29AM  Cramer's Lightning Round - BioMarin Is A Biotech Survivor (5/7/14) at Seeking Alpha
06-May-14 06:48PM  Lightning Round: Westport Innovations, Opko & More at CNBC
08:00AM  BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th GlobeNewswire
02-May-14 03:00PM  Loss at BioMarin Narrower Than Expected Zacks
12:16PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report EDGAR Online
09:13AM  BioMarin says change ups chance to hit cognition endpoint, says Janney Capital at theflyonthewall.com
06:11AM  BioMarin says BMN 165-302 study to be available in Q4 of 2015 theflyonthewall.com
12:50AM  BioMarin Pharmaceutical's CEO Discusses Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
01-May-14 06:14PM  BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales at Motley Fool
04:49PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:05PM  BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress GlobeNewswire
09:32AM  Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics Inc. at Motley Fool
07:07AM  Q1 2014 BioMarin Pharmaceutical Inc. Earnings Release - After Market Close CCBN
29-Apr-14 06:32PM  Better Biotech Buy: Vertex Pharmaceuticals Incorporated vs. BioMarin Pharmaceutical Inc. at Motley Fool
28-Apr-14 06:36PM  Cramer: Momentum stocks to fall much further? at CNBC
03:18PM  Cancer and Hepatitis C Treatment Breakthroughs Boost Pharma Stocks: Citigroup Investment Global Head of Healthcare Research & Analysis Andrew Baum, M.D. Interviews with the Wall Street Transcript Wall Street Transcript
01:08PM  Obamacare Worries Subside as Orphan Drugs and Oncology Treatments Retain Pricing Power: A Wall Street Transcript Interview with Boris Peaker, Ph.D., Executive Director and Senior Analyst with Oppenheimer & Co. Covering the Biotechnology Sec Wall Street Transcript
11:06AM  BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages GlobeNewswire
23-Apr-14 08:48AM  Do The Math: Ram Selvaraju On The Appeal Of Biotechs In Orphan Diseases at Seeking Alpha
17-Apr-14 06:32PM  How Are Orphan Drugmakers Faring in the Great Biotech Downturn? at Motley Fool
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Option Exercise27.2417,370473,16542,750Mar 10 06:16 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMar 06Sale78.6317,3701,365,83125,380Mar 10 06:16 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Option Exercise39.068,000312,48072,273Mar 05 04:40 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 03Sale80.328,000642,53064,273Mar 05 04:40 PM
Davis George EricSVP, General CounselFeb 20Option Exercise21.5120,000430,20080,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 20Sale80.008,000640,00046,740Feb 24 06:54 PM
Davis George EricSVP, General CounselFeb 20Sale80.0020,0001,600,00060,656Feb 24 06:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 06Option Exercise12.994,00051,96054,740Feb 07 04:53 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Option Exercise21.5110,000215,10052,350Feb 04 06:25 PM
FUCHS HENRY JEVP, Chief Medical OfficerFeb 03Sale67.7010,000676,96642,350Feb 04 06:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise12.995,00064,95055,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale70.005,000350,00050,740Jan 14 07:37 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Option Exercise12.9910,000129,90060,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 06Sale67.4110,000674,09650,740Jan 08 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Option Exercise12.995,00064,95055,740Jan 06 04:08 PM
FUCHS HENRY JEVP, Chief Medical OfficerJan 02Sale68.9791663,17242,350Jan 06 04:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 02Sale68.905,000344,48350,740Jan 06 04:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale68.7110,000687,14350,740Dec 27 12:07 PM
GREY MICHAEL GDirectorDec 11Option Exercise21.7130,000651,30053,050Dec 13 06:07 PM
GREY MICHAEL GDirectorDec 11Sale69.6630,0002,089,68023,050Dec 13 06:07 PM
LEWIS ALANDirectorDec 09Option Exercise30.5222,500686,77541,800Dec 11 08:21 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Option Exercise19.4413,026253,18327,906Dec 11 07:15 PM
LAWLIS V BRYANDirectorDec 09Sale69.762,900202,30111,400Dec 11 07:17 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 09Sale69.5513,026906,01014,880Dec 11 07:15 PM
LEWIS ALANDirectorDec 09Sale69.9122,5001,572,98219,300Dec 11 08:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 05Sale69.705,000348,48550,740Dec 09 07:42 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Option Exercise39.069,000351,54046,950Dec 04 04:15 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerDec 02Sale70.149,000631,27337,950Dec 04 04:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 14Option Exercise12.995,00064,95050,740Nov 18 05:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Option Exercise12.995,00064,95050,740Nov 07 05:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 05Sale62.365,000311,77945,740Nov 07 05:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 01Sale63.16996,25314,880Nov 05 07:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Option Exercise12.9910,000129,90055,740Nov 04 06:31 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 31Sale62.7210,000627,15545,740Nov 04 06:31 PM